MDxHealth SA (0O8G.L)

3.0198 -0.1804 (-5.64%) At close: 06:16PM BST

MDxHealth SA

CAP Business Center
Rue d’Abhooz 31 Zone Industrielle des Hauts-Sarts
Herstal 4040
Belgium
32 4 257 70 21
https://mdxhealth.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael K. McGarrity	CEO & Executive Director	533.4k	N/A	1963
Mr. Ron Kalfus	Chief Financial Officer	N/A	N/A	1974
Mr. Joseph Sollee	Executive VP of Corporate Development & General Counsel	N/A	N/A	1965
Mr. John A. Bellano	Chief Commercial Officer	N/A	N/A	1969
Ms. Miriam Reyes	Executive Vice President of Operations	N/A	N/A	1973
Dr. Jason Poole Ph.D.	Chief Scientific Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Corporate governance

MDxHealth SA’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 7; Board: 3; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.